Amedeo Minichino1, Grazia Rutigliano2, Sergio Merlino2, Cathy Davies2, Dominic Oliver2, Andrea De Micheli2, Rashmi Patel3, Philip McGuire3, Paolo Fusar-Poli4. 1. Early Psychosis: Interventions & Clinical-detection (EPIC) lab, Department of Psychosis Studies, King's College London, Institute of Psychiatry Psychology and Neuroscience, London, United Kingdom; Department of Psychiatry, University of Oxford, Oxford, United Kingdom. 2. Early Psychosis: Interventions & Clinical-detection (EPIC) lab, Department of Psychosis Studies, King's College London, Institute of Psychiatry Psychology and Neuroscience, London, United Kingdom. 3. Department of Psychosis Studies, King's College London, Institute of Psychiatry Psychology and Neuroscience, London, United Kingdom. 4. Early Psychosis: Interventions & Clinical-detection (EPIC) lab, Department of Psychosis Studies, King's College London, Institute of Psychiatry Psychology and Neuroscience, London, United Kingdom; OASIS Service, South London and the Maudsley NHS Foundation Trust, London, United Kingdom; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy. Electronic address: paolo.fusar-poli@kcl.ac.uk.
Abstract
BACKGROUND: Patients with acute and transient psychotic disorders (ATPDs) are by definition remitting, but have a high risk of developing persistent psychoses, resembling a subgroup of individuals at Clinical High Risk for Psychosis (CHR-P). Their pathways to care, treatment offered and long-term clinical outcomes beyond risk to psychosis are unexplored. We conducted an electronic health record-based retrospective cohort study including patients with ATPDs within the SLaM NHS Trust and followed-up to 8 years. METHODS: A total of 2561 ATPDs were included in the study. A minority were detected (8%) and treated (18%) by Early Intervention services (EIS) and none by CHR-P services. Patients were offered a clinical follow-up of 350.40 ± 589.90 days. The cumulative incidence of discharges was 40% at 3 months, 60% at 1 year, 69% at 2 years, 77% at 4 years, and 82% at 8 years. Treatment was heterogeneous: the majority of patients received antipsychotics (up to 52%), only a tiny minority psychotherapy (up to 8%). RESULTS: Over follow-up, 32.88% and 28.54% of ATPDS received at least one mental health hospitalization or one compulsory hospital admission under the Mental Health Act, respectively. The mean number of days spent in psychiatric hospital was 66.39 ± 239.44 days. CONCLUSIONS: The majority of ATPDs are not detected/treated by EIS or CHR-P services, receive heterogeneous treatments and short-term clinical follow-up. ATPDs have a high risk of developing severe clinical outcomes beyond persistent psychotic disorders and unmet clinical needs that are not targeted by current mental health services.
BACKGROUND:Patients with acute and transient psychotic disorders (ATPDs) are by definition remitting, but have a high risk of developing persistent psychoses, resembling a subgroup of individuals at Clinical High Risk for Psychosis (CHR-P). Their pathways to care, treatment offered and long-term clinical outcomes beyond risk to psychosis are unexplored. We conducted an electronic health record-based retrospective cohort study including patients with ATPDs within the SLaM NHS Trust and followed-up to 8 years. METHODS: A total of 2561 ATPDs were included in the study. A minority were detected (8%) and treated (18%) by Early Intervention services (EIS) and none by CHR-P services. Patients were offered a clinical follow-up of 350.40 ± 589.90 days. The cumulative incidence of discharges was 40% at 3 months, 60% at 1 year, 69% at 2 years, 77% at 4 years, and 82% at 8 years. Treatment was heterogeneous: the majority of patients received antipsychotics (up to 52%), only a tiny minority psychotherapy (up to 8%). RESULTS: Over follow-up, 32.88% and 28.54% of ATPDS received at least one mental health hospitalization or one compulsory hospital admission under the Mental Health Act, respectively. The mean number of days spent in psychiatric hospital was 66.39 ± 239.44 days. CONCLUSIONS: The majority of ATPDs are not detected/treated by EIS or CHR-P services, receive heterogeneous treatments and short-term clinical follow-up. ATPDs have a high risk of developing severe clinical outcomes beyond persistent psychotic disorders and unmet clinical needs that are not targeted by current mental health services.
Authors: Ilaria Bonoldi; Paul Allen; Luis Madeira; Stefania Tognin; Matthijs G Bossong; Mathilda Azis; Carly Samson; Beverly Quinn; Maria Calem; Lucia Valmaggia; Gemma Modinos; James Stone; Jesus Perez; Oliver Howes; Pierluigi Politi; Matthew J Kempton; Paolo Fusar-Poli; Philip McGuire Journal: Front Psychiatry Date: 2019-05-10 Impact factor: 4.157
Authors: Paolo Fusar-Poli; Cathy Davies; Marco Solmi; Natascia Brondino; Andrea De Micheli; Magdalena Kotlicka-Antczak; Jae Il Shin; Joaquim Radua Journal: Front Psychiatry Date: 2019-12-11 Impact factor: 4.157
Authors: Paolo Fusar-Poli; Dominic Stringer; Alice M S Durieux; Grazia Rutigliano; Ilaria Bonoldi; Andrea De Micheli; Daniel Stahl Journal: Transl Psychiatry Date: 2019-10-17 Impact factor: 6.222
Authors: Gonzalo Salazar de Pablo; Daniel Guinart; Barbara A Cornblatt; Andrea M Auther; Ricardo E Carrión; Maren Carbon; Sara Jiménez-Fernández; Ditte L Vernal; Susanne Walitza; Miriam Gerstenberg; Riccardo Saba; Nella Lo Cascio; Martina Brandizzi; Celso Arango; Carmen Moreno; Anna Van Meter; Paolo Fusar-Poli; Christoph U Correll Journal: Front Psychiatry Date: 2020-10-21 Impact factor: 4.157
Authors: Dominic Oliver; Chiew Meng Johnny Wong; Martin Bøg; Linus Jönsson; Bruce J Kinon; Allan Wehnert; Kristian Tore Jørgensen; Jessica Irving; Daniel Stahl; Philip McGuire; Lars Lau Raket; Paolo Fusar-Poli Journal: Transl Psychiatry Date: 2020-10-29 Impact factor: 6.222